IL2 and metastatic melanoma: Since its discovery in 1976 and the subsequent understanding of its vital role as a lymphocyte T-cell growth factor, the cytokine IL-2 was approved in the 1990s for use in patients with advanced-stage cancer, including RCC and later for metastatic melanoma.